{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T02:51:00Z","timestamp":1790823060587,"version":"4.1.0"},"reference-count":202,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.bbcan.2014.05.004","type":"journal-article","created":{"date-parts":[[2014,5,28]],"date-time":"2014-05-28T12:00:35Z","timestamp":1401278435000},"page":"326-341","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":89,"title":["The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongation"],"prefix":"10.1016","volume":"1846","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5651-3997","authenticated-orcid":false,"given":"Remco J.","family":"Molenaar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9701-1851","authenticated-orcid":false,"given":"Tomas","family":"Radivoyevitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaroslaw P.","family":"Maciejewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelis J.F.","family":"van Noorden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fonnet E.","family":"Bleeker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbcan.2014.05.004_bb0505","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1126\/science.1164382","article-title":"An integrated genomic analysis of human glioblastoma multiforme","volume":"321","author":"Parsons","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.bbcan.2014.05.004_bb0510","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1056\/NEJMoa0808710","article-title":"IDH1 and IDH2 mutations in gliomas","volume":"360","author":"Yan","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0515","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1056\/NEJMoa0903840","article-title":"Recurring mutations found by sequencing an acute myeloid leukemia genome","volume":"361","author":"Mardis","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0520","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1634\/theoncologist.2011-0386","article-title":"Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping","volume":"17","author":"Borger","year":"2012","journal-title":"Oncologist"},{"key":"10.1016\/j.bbcan.2014.05.004_bb0525","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1038\/onc.2012.315","article-title":"Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas","volume":"32","author":"Wang","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.bbcan.2014.05.004_bb0530","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1038\/ng.2813","article-title":"Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas","volume":"45","author":"Jiao","year":"2013","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0535","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1038\/ng.2806","article-title":"Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers","volume":"45","author":"Chan-On","year":"2013","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0540","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1182\/blood-2011-11-391748","article-title":"IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma","volume":"119","author":"Cairns","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2014.05.004_bb0545","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/path.2913","article-title":"IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours","volume":"224","author":"Amary","year":"2011","journal-title":"J. Pathol."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0550","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/ng.994","article-title":"Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2","volume":"43","author":"Amary","year":"2011","journal-title":"Nat. Genet."},{"issue":"8","key":"10.1016\/j.bbcan.2014.05.004_bb1020","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/ng.2668","article-title":"Frequent mutation of the major cartilage collagen gene COL2A1 in chondrosarcoma","volume":"45","author":"Tarpey","year":"2013","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0560","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/ijc.24379","article-title":"Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers","volume":"125","author":"Kang","year":"2009","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bbcan.2014.05.004_bb0565","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1126\/science.1192632","article-title":"IDH2 mutations in patients with D-2-hydroxyglutaric aciduria","volume":"330","author":"Kranendijk","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.bbcan.2014.05.004_bb0570","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.bbcan.2014.05.004_bb0575","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/nature08617","article-title":"Cancer-associated IDH1 mutations produce 2-hydroxyglutarate","volume":"462","author":"Dang","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2014.05.004_bb0580","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/embor.2011.43","article-title":"The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases","volume":"12","author":"Chowdhury","year":"2011","journal-title":"EMBO Rep."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0585","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ccr.2010.12.014","article-title":"Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases","volume":"19","author":"Xu","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbcan.2014.05.004_bb0590","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/nature10898","article-title":"Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation","volume":"483","author":"Koivunen","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2014.05.004_bb0595","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ccr.2010.11.015","article-title":"Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation","volume":"18","author":"Figueroa","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbcan.2014.05.004_bb0600","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1101\/gad.217406.113","article-title":"What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer","volume":"27","author":"Losman","year":"2013","journal-title":"Genes Dev."},{"key":"10.1016\/j.bbcan.2014.05.004_bb1025","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1101\/gad.198200.112","article-title":"D-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function","volume":"26","author":"Sasaki","year":"2012","journal-title":"Genes Dev."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0610","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/nature10860","article-title":"IDH mutation impairs histone demethylation and results in a block to cell differentiation","volume":"483","author":"Lu","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2014.05.004_bb0615","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1182\/blood-2009-11-250878","article-title":"Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value","volume":"116","author":"Abbas","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2014.05.004_bb0620","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1126\/science.1236062","article-title":"An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells","volume":"340","author":"Rohle","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.bbcan.2014.05.004_bb0625","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1126\/science.1234769","article-title":"Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation","volume":"340","author":"Wang","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.bbcan.2014.05.004_bb0630","doi-asserted-by":"crossref","first-page":"14615","DOI":"10.1074\/jbc.C112.353946","article-title":"Cancer-associated isocitrate dehydrogenase mutations inactivate NADPH-dependent reductive carboxylation","volume":"287","author":"Leonardi","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0635","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1897\/02-364","article-title":"Reduced nicotinamide adenine dinucleotide phosphate and the higher incidence of pollution-induced liver cancer in female flounder","volume":"22","author":"Koehler","year":"2003","journal-title":"Environ. Toxicol. Chem."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0640","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.bbrc.2010.03.083","article-title":"Thioredoxin and thioredoxin reductase: current research with special reference to human disease","volume":"396","author":"Holmgren","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0645","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1074\/jbc.274.5.2750","article-title":"Enhanced glutathione levels and oxidoresistance mediated by increased glucose-6-phosphate dehydrogenase expression","volume":"274","author":"Salvemini","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0650","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/BF01675217","article-title":"A quantitative histochemical study of NADPH-ferrihemoprotein reductase activity","volume":"18","author":"Van Noorden","year":"1986","journal-title":"Histochem. J."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0655","first-page":"793","article-title":"Multiple roles of glutathione in the central nervous system","volume":"378","author":"Cooper","year":"1997","journal-title":"Biol. Chem."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0660","doi-asserted-by":"crossref","first-page":"3804","DOI":"10.1128\/JB.00046-09","article-title":"Alpha-ketoglutarate dehydrogenase and glutamate dehydrogenase work in tandem to modulate the antioxidant alpha-ketoglutarate during oxidative stress in Pseudomonas fluorescens","volume":"191","author":"Mailloux","year":"2009","journal-title":"J. Bacteriol."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0665","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.freeradbiomed.2006.02.012","article-title":"Nonenzymatic formation of succinate in mitochondria under oxidative stress","volume":"41","author":"Fedotcheva","year":"2006","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0670","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1369\/0022155411400606","article-title":"Differential activity of NADPH-producing dehydrogenases renders rodents unsuitable models to study IDH1R132 mutation effects in human glioblastoma","volume":"59","author":"Atai","year":"2011","journal-title":"J. Histochem. Cytochem."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0675","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00401-010-0645-6","article-title":"The prognostic IDH1(R132) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma","volume":"119","author":"Bleeker","year":"2010","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0680","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0140-6736(08)60073-2","article-title":"Glucose-6-phosphate dehydrogenase deficiency","volume":"371","author":"Cappellini","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.bbcan.2014.05.004_bb0685","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/nature10642","article-title":"Reductive carboxylation supports growth in tumour cells with defective mitochondria","volume":"481","author":"Mullen","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2014.05.004_bb0690","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/nature10602","article-title":"Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia","volume":"481","author":"Metallo","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2014.05.004_bb0695","doi-asserted-by":"crossref","first-page":"19611","DOI":"10.1073\/pnas.1117773108","article-title":"Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of alpha-ketoglutarate to citrate to support cell growth and viability","volume":"108","author":"Wise","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"12","key":"10.1016\/j.bbcan.2014.05.004_bb1030","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.1158\/0008-5472.CAN-14-0772-T","article-title":"IDH1 mutations alter citric acid cycle metabolism and increase dependence on oxidative mitochondrial metabolism","volume":"74","author":"Grassian","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0705","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s00401-008-0455-2","article-title":"Analysis of the IDH1 codon 132 mutation in brain tumors","volume":"116","author":"Balss","year":"2008","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0710","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1215\/15228517-2009-025","article-title":"IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas","volume":"11","author":"Ichimura","year":"2009","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0715","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.2353\/ajpath.2009.080958","article-title":"IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas","volume":"174","author":"Watanabe","year":"2009","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0720","doi-asserted-by":"crossref","first-page":"4150","DOI":"10.1200\/JCO.2009.21.9832","article-title":"Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas","volume":"27","author":"Sanson","year":"2009","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0725","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/humu.20937","article-title":"IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors","volume":"30","author":"Bleeker","year":"2009","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.bbcan.2014.05.004_bb1035","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1093\/neuonc\/not043","article-title":"Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collective","volume":"15","author":"Wiestler","year":"2013","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0735","article-title":"Deep sequencing identifies IDH1 R132S mutation in adult medulloblastoma","author":"Snuderl","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0740","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1126\/science.1239947","article-title":"Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma","volume":"343","author":"Johnson","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.bbcan.2014.05.004_bb0745","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11060-011-0793-0","article-title":"Recent advances in the molecular understanding of glioblastoma","volume":"108","author":"Bleeker","year":"2012","journal-title":"J. Neurooncol."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0750","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/modpathol.2012.210","article-title":"Expanding the spectrum of IDH1 mutations in gliomas","volume":"26","author":"Gupta","year":"2013","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0755","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1365-2990.2010.01127.x","article-title":"Glioma IDH1 mutation patterns off the beaten track","volume":"37","author":"Pusch","year":"2011","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0760","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1182\/blood-2009-11-253070","article-title":"Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation","volume":"115","author":"Chou","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2014.05.004_bb0765","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1038\/leu.2010.113","article-title":"IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis","volume":"24","author":"Tefferi","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.bbcan.2014.05.004_bb0770","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1200\/JCO.2009.27.3730","article-title":"IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study","volume":"28","author":"Marcucci","year":"2010","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0775","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.3109\/10428194.2012.695359","article-title":"Potential application of IDH1 and IDH2 mutations as prognostic indicators in non-promyelocytic acute myeloid leukemia: a meta-analysis","volume":"53","author":"Zhou","year":"2012","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.bbcan.2014.05.004_bb0780","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1182\/blood-2010-12-322479","article-title":"The prognostic significance of IDH2 mutations in AML depends on the location of the mutation","volume":"118","author":"Green","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2014.05.004_bb0785","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/leu.2011.253","article-title":"IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F","volume":"26","author":"Tefferi","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.bbcan.2014.05.004_bb0790","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.3324\/haematol.2010.025494","article-title":"IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis","volume":"95","author":"Thol","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.bbcan.2014.05.004_bb0795","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1126\/science.1133427","article-title":"The consensus coding sequences of human breast and colorectal cancers","volume":"314","author":"Sjoblom","year":"2006","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.bbcan.2014.05.004_bb1040","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1007\/s10120-013-0315-1","article-title":"High-throughput mutation profiling identifies novel molecular dysregulation in high-grade intraepithelial neoplasia and early gastric cancers","volume":"17","author":"Fassan","year":"2014","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.bbcan.2014.05.004_bb0805","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.bbrc.2010.06.125","article-title":"IDH1(R132) mutation identified in one human melanoma metastasis, but not correlated with metastases to the brain","volume":"398","author":"Lopez","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0810","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1093\/annonc\/mdr489","article-title":"Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice","volume":"22","author":"Sequist","year":"2011","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0815","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/cam4.149","article-title":"Isocitrate dehydrogenase 2 mutation is a frequent event in osteosarcoma detected by a multi-specific monoclonal antibody MsMab-1","volume":"2","author":"Liu","year":"2013","journal-title":"Cancer Med."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0820","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1210\/jc.2009-2170","article-title":"Isocitrate dehydrogenase mutations are rare in pheochromocytomas and paragangliomas","volume":"95","author":"Gaal","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0825","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/ng.1004","article-title":"Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome","volume":"43","author":"Pansuriya","year":"2011","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0830","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1136\/jmedgenet-2013-101961","article-title":"Novel cases of D-2-hydroxyglutaric aciduria with IDH1 or IDH2 mosaic mutations identified by amplicon deep sequencing","volume":"50","author":"Nota","year":"2013","journal-title":"J. Med. Genet."},{"issue":"3","key":"10.1016\/j.bbcan.2014.05.004_bb1045","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/cas.12337","article-title":"IDH2 and TP53 mutations are correlated with gliomagenesis in a patient with Maffucci syndrome","volume":"105","author":"Moriya","year":"2014","journal-title":"Cancer Sci."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0840","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s10545-012-9462-5","article-title":"Progress in understanding 2-hydroxyglutaric acidurias","volume":"35","author":"Kranendijk","year":"2012","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0845","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1101\/gad.231233.113","article-title":"D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice","volume":"28","author":"Akbay","year":"2014","journal-title":"Genes Dev."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0850","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1126\/science.1170944","article-title":"Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha","volume":"324","author":"Zhao","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.bbcan.2014.05.004_bb0855","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ccr.2010.01.020","article-title":"The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate","volume":"17","author":"Ward","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbcan.2014.05.004_bb0860","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1084\/jem.20092506","article-title":"Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations","volume":"207","author":"Gross","year":"2010","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0865","doi-asserted-by":"crossref","first-page":"4649","DOI":"10.1182\/blood-2012-06-438267","article-title":"Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response","volume":"120","author":"Fathi","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2014.05.004_bb0870","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.1600-0609.2010.01505.x","article-title":"Increased levels of 2-hydroxyglutarate in AML patients with IDH1-R132H and IDH2-R140Q mutations","volume":"85","author":"Sellner","year":"2010","journal-title":"Eur. J. Haematol."},{"issue":"4","key":"10.1016\/j.bbcan.2014.05.004_bb0875","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1200\/JCO.2013.50.2047","article-title":"Serum 2-hydroxyglutarate production in IDH1- and IDH2-mutated de novo acute myeloid leukemia: a study by the Acute Leukemia French Association Group","volume":"32","author":"Janin","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0880","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1158\/1078-0432.CCR-13-2649","article-title":"Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma","volume":"20","author":"Borger","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bbcan.2014.05.004_bb1050","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/bjh.12826","article-title":"Elevated plasma 2-hydroxyglutarate in acute myeloid leukaemia: association with the IDH1 SNP rs11554137 and severe renal impairment","volume":"166","author":"Wiseman","year":"2014","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0890","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/nm.2682","article-title":"2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas","volume":"18","author":"Choi","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0895","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1038\/ncomms3429","article-title":"Non-invasive in vivo assessment of IDH1 mutational status in glioma","volume":"4","author":"Chaumeil","year":"2013","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0900","doi-asserted-by":"crossref","first-page":"3659","DOI":"10.1172\/JCI67229","article-title":"Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxyglutarate","volume":"123","author":"Andronesi","year":"2013","journal-title":"J. Clin. Invest."},{"issue":"5","key":"10.1016\/j.bbcan.2014.05.004_bb1055","doi-asserted-by":"crossref","first-page":"920","DOI":"10.3174\/ajnr.A3803","article-title":"Can diffusion tensor imaging noninvasively detect IDH1 gene mutations in astrogliomas? A retrospective study of 112 cases","volume":"35","author":"Tan","year":"2014","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0910","doi-asserted-by":"crossref","first-page":"e16812","DOI":"10.1371\/journal.pone.0016812","article-title":"2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations","volume":"6","author":"Jin","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bbcan.2014.05.004_bb0915","doi-asserted-by":"crossref","first-page":"3804","DOI":"10.1074\/jbc.M112.435495","article-title":"The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization","volume":"288","author":"Ward","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0920","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/2051-5960-2-19","article-title":"D-2-Hydroxyglutarate producing neo-enzymatic activity inversely correlates with frequency of the type of isocitrate dehydrogenase 1 mutations found in glioma","volume":"2","author":"Pusch","year":"2014","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0925","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s00401-013-1106-9","article-title":"What do we know about IDH1\/2 mutations so far, and how do we use it?","volume":"125","author":"Horbinski","year":"2013","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0930","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1038\/onc.2011.416","article-title":"Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production","volume":"31","author":"Ward","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.bbcan.2014.05.004_bb0935","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1101\/gad.226753.113","article-title":"Induction of sarcomas by mutant IDH2","volume":"27","author":"Lu","year":"2013","journal-title":"Genes Dev."},{"issue":"2013","key":"10.1016\/j.bbcan.2014.05.004_bb0940","article-title":"Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition","volume":"27","author":"Chen","year":"1974","journal-title":"Genes Dev."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0945","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.stem.2013.12.016","article-title":"Proto-oncogenic role of mutant IDH2 in leukemia initiation and maintenance","volume":"14","author":"Kats","year":"2014","journal-title":"Cell Stem Cell"},{"issue":"6","key":"10.1016\/j.bbcan.2014.05.004_bb1060","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1038\/leu.2014.18","article-title":"Isocitrate dehydrogenase (IDH)2 R140Q mutation induces myeloid and lymphoid neoplasms in mice","volume":"28","author":"Mylonas","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.bbcan.2014.05.004_bb0955","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1172\/JCI71180","article-title":"MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis","volume":"124","author":"Terunuma","year":"2014","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bbcan.2014.05.004_bb1065","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1126\/science.1231677","article-title":"(R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible","volume":"339","author":"Losman","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.bbcan.2014.05.004_bb0965","doi-asserted-by":"crossref","first-page":"3423","DOI":"10.1038\/ncomms4423","article-title":"Non-enzymatic chemistry enables 2-hydroxyglutarate-mediated activation of 2-oxoglutarate oxygenases","volume":"5","author":"Tarhonskaya","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0970","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.molcel.2008.04.009","article-title":"Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway","volume":"30","author":"Kaelin","year":"2008","journal-title":"Mol. Cell"},{"issue":"5","key":"10.1016\/j.bbcan.2014.05.004_bb1070","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1093\/neuonc\/not243","article-title":"Lactate dehydrogenase A silencing in IDH mutant gliomas","volume":"16","author":"Chesnelong","year":"2014","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0980","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/onc.2009.441","article-title":"Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics","volume":"29","author":"Semenza","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.bbcan.2014.05.004_bb0985","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.stem.2010.06.020","article-title":"Regulation of the HIF-1alpha level is essential for hematopoietic stem cells","volume":"7","author":"Takubo","year":"2010","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.bbcan.2014.05.004_bb0990","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1182\/blood-2012-02-408419","article-title":"Pharmacologic stabilization of HIF-1alpha increases hematopoietic stem cell quiescence in vivo and accelerates blood recovery after severe irradiation","volume":"121","author":"Forristal","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2014.05.004_bb0995","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/sj.onc.1210670","article-title":"Hypoxia-inducible factor-1alpha-induced differentiation of myeloid leukemic cells is its transcriptional activity independent","volume":"27","author":"Song","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.bbcan.2014.05.004_bb1000","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ccr.2005.07.003","article-title":"Genetic evidence for a tumor suppressor role of HIF-2alpha","volume":"8","author":"Acker","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbcan.2014.05.004_bb1005","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S1535-6108(03)00194-6","article-title":"The hypoxic response of tumors is dependent on their microenvironment","volume":"4","author":"Blouw","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbcan.2014.05.004_bb1010","doi-asserted-by":"crossref","first-page":"7249","DOI":"10.1158\/0008-5472.CAN-04-4426","article-title":"Evaluating hypoxia-inducible factor-1alpha as a cancer therapeutic target via inducible RNA interference in vivo","volume":"65","author":"Li","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2014.05.004_bb1015","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1021\/mp800192d","article-title":"Targeted systemic delivery of a therapeutic siRNA with a multifunctional carrier controls tumor proliferation in mice","volume":"6","author":"Wang","year":"2009","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0010","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1002\/1097-0142(20000601)88:11<2606::AID-CNCR25>3.0.CO;2-W","article-title":"Expression of hypoxia-inducible factor 1alpha in brain tumors: association with angiogenesis, invasion, and progression","volume":"88","author":"Zagzag","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.bbcan.2014.05.004_bb1075","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/nature07385","article-title":"Comprehensive genomic characterization defines human glioblastoma genes and core pathways","volume":"455","author":"TCGAN","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2014.05.004_bb0020","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s00401-010-0790-y","article-title":"R132H-mutation of isocitrate dehydrogenase-1 is not sufficient for HIF-1alpha upregulation in adult glioma","volume":"121","author":"Williams","year":"2011","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0025","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00401-007-0243-4","article-title":"The 2007 WHO classification of tumours of the central nervous system","volume":"114","author":"Louis","year":"2007","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0030","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1158\/1078-0432.CCR-12-3002","article-title":"The definition of primary and secondary glioblastoma","volume":"19","author":"Ohgaki","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0035","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1476-4598-8-71","article-title":"Meta-analysis of glioblastoma multiforme versus anaplastic astrocytoma identifies robust gene markers","volume":"8","author":"Dreyfuss","year":"2009","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bbcan.2014.05.004_bb0040","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.2353\/ajpath.2007.070011","article-title":"Genetic pathways to primary and secondary glioblastoma","volume":"170","author":"Ohgaki","year":"2007","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0045","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.ccr.2012.02.014","article-title":"Metabolic reprogramming: a cancer hallmark even warburg did not anticipate","volume":"21","author":"Ward","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbcan.2014.05.004_bb0050","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/nrc3343","article-title":"The role of mutations in epigenetic regulators in myeloid malignancies","volume":"12","author":"Shih","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbcan.2014.05.004_bb0055","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1038\/ncomms3166","article-title":"Meta-analysis of IDH-mutant cancers identifies EBF1 as an interaction partner for TET2","volume":"4","author":"Guilhamon","year":"2013","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0060","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1101\/gr.132738.111","article-title":"A heterozygous IDH1R132H\/WT mutation induces genome-wide alterations in DNA methylation","volume":"22","author":"Duncan","year":"2012","journal-title":"Genome Res."},{"issue":"16","key":"10.1016\/j.bbcan.2014.05.004_bb1080","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1182\/blood-2013-03-491571","article-title":"Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML","volume":"122","author":"Chaturvedi","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2014.05.004_bb0070","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1182\/blood-2009-03-210039","article-title":"Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies","volume":"114","author":"Abdel-Wahab","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2014.05.004_bb0075","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1182\/blood-2011-02-339747","article-title":"TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics","volume":"118","author":"Chou","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2014.05.004_bb0080","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/leu.2009.47","article-title":"TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis","volume":"23","author":"Tefferi","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.bbcan.2014.05.004_bb0085","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1200\/JCO.2011.39.2886","article-title":"TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group","volume":"30","author":"Gaidzik","year":"2012","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0090","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1136\/jclinpath-2011-200133","article-title":"TET2 promoter methylation in low-grade diffuse gliomas lacking IDH1\/2 mutations","volume":"64","author":"Kim","year":"2011","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0095","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.18632\/oncotarget.1412","article-title":"Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT inhibitor decitabine","volume":"4","author":"Turcan","year":"2013","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbcan.2014.05.004_bb0100","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.18632\/oncotarget.1408","article-title":"5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft","volume":"4","author":"Borodovsky","year":"2013","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbcan.2014.05.004_bb0105","first-page":"75","article-title":"Histone lysine methylation and demethylation pathways in cancer","volume":"1815","author":"Varier","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bbcan.2014.05.004_bb0110","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/nature06255","article-title":"JHDM1B\/FBXL10 is a nucleolar protein that represses transcription of ribosomal RNA genes","volume":"450","author":"Frescas","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2014.05.004_bb0115","doi-asserted-by":"crossref","first-page":"6946","DOI":"10.1038\/sj.onc.1204850","article-title":"A novel nuclear protein, 5qNCA (LOC51780) is a candidate for the myeloid leukemia tumor suppressor gene on chromosome 5 band q31","volume":"20","author":"Hu","year":"2001","journal-title":"Oncogene"},{"key":"10.1016\/j.bbcan.2014.05.004_bb0120","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/nature11323","article-title":"IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics","volume":"488","author":"Sasaki","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2014.05.004_bb0125","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.ccr.2010.03.017","article-title":"Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma","volume":"17","author":"Noushmehr","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbcan.2014.05.004_bb0130","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/nature10866","article-title":"IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype","volume":"483","author":"Turcan","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2014.05.004_bb0135","doi-asserted-by":"crossref","first-page":"201","DOI":"10.4161\/epi.7.2.19015","article-title":"Effects of TET2 mutations on DNA methylation in chronic myelomonocytic leukemia","volume":"7","author":"Yamazaki","year":"2012","journal-title":"Epigenetics"},{"key":"10.1016\/j.bbcan.2014.05.004_bb0140","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/nature09586","article-title":"Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2","volume":"468","author":"Ko","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2014.05.004_bb0145","doi-asserted-by":"crossref","first-page":"e31605","DOI":"10.1371\/journal.pone.0031605","article-title":"TET2 mutations are associated with specific 5-methylcytosine and 5-hydroxymethylcytosine profiles in patients with chronic myelomonocytic leukemia","volume":"7","author":"Perez","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bbcan.2014.05.004_bb0150","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1200\/JCO.2010.32.7742","article-title":"TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a cancer and leukemia group B study","volume":"29","author":"Metzeler","year":"2011","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.bbcan.2014.05.004_bb0155","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1158\/2159-8290.CD-13-0083","article-title":"Oncogenic isocitrate dehydrogenase mutations: mechanisms, models, and clinical opportunities","volume":"3","author":"Cairns","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0160","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s10529-011-0800-8","article-title":"Mutations in isocitrate dehydrogenase 2 accelerate glioma cell migration via matrix metalloproteinase-2 and 9","volume":"34","author":"Fu","year":"2012","journal-title":"Biotechnol. Lett."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0165","first-page":"69","article-title":"The role of gelatinases in colorectal cancer progression and metastasis","volume":"1705","author":"Mook","year":"2004","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bbcan.2014.05.004_bb1085","series-title":"The Collagens: Biochemistry and Pathophysiology","first-page":"261","article-title":"Collagen in the nervous system","author":"Kucharz","year":"1992"},{"key":"10.1016\/j.bbcan.2014.05.004_bb0175","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1046\/j.1460-9568.2002.02055.x","article-title":"NMDA receptor activation and respiratory chain complex V inhibition contribute to neurodegeneration in d-2-hydroxyglutaric aciduria","volume":"16","author":"Kolker","year":"2002","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0180","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1046\/j.1460-9568.2003.02639.x","article-title":"D-2-hydroxyglutaric acid induces oxidative stress in cerebral cortex of young rats","volume":"17","author":"Latini","year":"2003","journal-title":"Eur. J. Neurosci."},{"issue":"2","key":"10.1016\/j.bbcan.2014.05.004_bb1090","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00401-013-1194-6","article-title":"Autophagy and oxidative stress in gliomas with IDH1 mutations","volume":"127","author":"Gilbert","year":"2014","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0190","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1038\/cr.2010.145","article-title":"Molecular mechanisms of \u201coff\u2013on switch\u201d of activities of human IDH1 by tumor-associated mutation R132H","volume":"20","author":"Yang","year":"2010","journal-title":"Cell Res."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0195","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.arr.2012.10.004","article-title":"Oxidative stress and cancer: an overview","volume":"12","author":"Sosa","year":"2013","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0200","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.stem.2010.11.028","article-title":"Proliferative neural stem cells have high endogenous ROS levels that regulate self-renewal and neurogenesis in a PI3K\/Akt-dependant manner","volume":"8","author":"Le Belle","year":"2011","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.bbcan.2014.05.004_bb0205","doi-asserted-by":"crossref","first-page":"4253","DOI":"10.1182\/blood-2011-10-385658","article-title":"Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors","volume":"119","author":"Nieborowska-Skorska","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2014.05.004_bb0210","doi-asserted-by":"crossref","DOI":"10.1186\/2051-5960-1-18","article-title":"Increased mitochondrial activity in a novel IDH1-R132H mutant human oligodendroglioma xenograft model: in situ detection of 2-HG and \u03b1-KG","volume":"1","author":"Navis","year":"2013","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0215","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/ana.22390","article-title":"IDH1 R132H decreases proliferation of glioma cell lines in vitro and in vivo","volume":"69","author":"Bralten","year":"2011","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0220","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/neuonc\/nos261","article-title":"Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation","volume":"15","author":"Li","year":"2013","journal-title":"Neuro Oncol."},{"issue":"6","key":"10.1016\/j.bbcan.2014.05.004_bb1095","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s10072-013-1607-2","article-title":"An IDH1 mutation inhibits growth of glioma cells via GSH depletion and ROS generation","volume":"35","author":"Shi","year":"2014","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0230","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s12031-012-9890-6","article-title":"Expression of R132H mutational IDH1 in human U87 glioblastoma cells affects the SREBP1a pathway and induces cellular proliferation","volume":"50","author":"Zhu","year":"2013","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0235","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.3892\/mmr.2014.2052","article-title":"Mutation of isocitrate dehydrogenase 1 induces glioma cell proliferation via nuclear factorkappaB activation in a hypoxiainducible factor 1alpha dependent manner","volume":"9","author":"Wang","year":"2014","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0240","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s11060-012-0831-6","article-title":"1P19Q loss but not IDH1 mutations influences WHO grade II gliomas spontaneous growth","volume":"108","author":"Goze","year":"2012","journal-title":"J. Neurooncol."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0245","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/nm.3217","article-title":"BCAT1 promotes cell proliferation through amino acid catabolism in gliomas carrying wild-type IDH1","volume":"19","author":"Tonjes","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0250","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/ng.890","article-title":"Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis","volume":"43","author":"Locasale","year":"2011","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0255","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nature10350","article-title":"Functional genomics reveal that the serine synthesis pathway is essential in breast cancer","volume":"476","author":"Possemato","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2014.05.004_bb0260","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1126\/science.1218595","article-title":"Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation","volume":"336","author":"Jain","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.bbcan.2014.05.004_bb0265","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1093\/brain\/awm204","article-title":"Long-term survival with glioblastoma multiforme","volume":"130","author":"Krex","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.bbcan.2014.05.004_bb0270","doi-asserted-by":"crossref","first-page":"5743","DOI":"10.1200\/JCO.2009.23.0805","article-title":"Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network","volume":"27","author":"Weller","year":"2009","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.bbcan.2014.05.004_bb1100","first-page":"414","article-title":"The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone","volume":"16","author":"Molenaar","year":"2014","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0280","doi-asserted-by":"crossref","first-page":"4482","DOI":"10.1200\/JCO.2010.33.8715","article-title":"Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin","volume":"29","author":"Lai","year":"2011","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0285","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.3174\/ajnr.A2950","article-title":"Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma","volume":"33","author":"Carrillo","year":"2012","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0290","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1097\/00005072-200606000-00001","article-title":"\u2018Pseudopalisading\u2019 necrosis in glioblastoma: a familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis","volume":"65","author":"Rong","year":"2006","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0295","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/neuonc\/not159","article-title":"IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection","volume":"16","author":"Beiko","year":"2014","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0300","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s11060-012-0837-0","article-title":"Immunohistochemical detection of IDH1 mutation, p53, and internexin as prognostic factors of glial tumors","volume":"108","author":"Takano","year":"2012","journal-title":"J. Neurooncol."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0305","doi-asserted-by":"crossref","first-page":"4588","DOI":"10.1158\/1078-0432.CCR-10-3194","article-title":"Molecular markers in low-grade gliomas: predictive or prognostic?","volume":"17","author":"Hartmann","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0310","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.3892\/ijo.2012.1564","article-title":"IDH1\/2 mutation is a prognostic marker for survival and predicts response to chemotherapy for grade II gliomas concomitantly treated with radiation therapy","volume":"41","author":"Okita","year":"2012","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0315","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1212\/WNL.0b013e3181f96282","article-title":"IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas","volume":"75","author":"Houillier","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.bbcan.2014.05.004_bb0320","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1349-7006.2011.02134.x","article-title":"IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma","volume":"103","author":"SongTao","year":"2012","journal-title":"Cancer Sci."},{"issue":"3","key":"10.1016\/j.bbcan.2014.05.004_bb1105","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1093\/neuonc\/not198","article-title":"Increased sensitivity to radiochemotherapy in IDH1 mutant glioblastoma as demonstrated by serial quantitative MR volumetry","volume":"16","author":"Tran","year":"2014","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0330","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s11060-012-0977-2","article-title":"The prognostic value of IDH mutations and MGMT promoter status in secondary high-grade gliomas","volume":"110","author":"Juratli","year":"2012","journal-title":"J. Neurooncol."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0335","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/1476-4598-9-133","article-title":"Knock down of HIF-1alpha in glioma cells reduces migration in vitro and invasion in vivo and impairs their ability to form tumor spheres","volume":"9","author":"Mendez","year":"2010","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bbcan.2014.05.004_bb0340","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0345","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0350","doi-asserted-by":"crossref","first-page":"7148","DOI":"10.1158\/1078-0432.CCR-11-1274","article-title":"A hypermethylated phenotype is a better predictor of survival than MGMT methylation in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951","volume":"17","author":"van den Bent","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0355","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s00401-010-0781-z","article-title":"Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas","volume":"120","author":"Hartmann","year":"2010","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0360","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1212\/WNL.0b013e3182a95680","article-title":"Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation","volume":"81","author":"Wick","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.bbcan.2014.05.004_bb0365","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1007\/s10495-013-0877-8","article-title":"Isocitrate dehydrogenase 1 mutant R132H sensitizes glioma cells to BCNU-induced oxidative stress and cell death","volume":"18","author":"Mohrenz","year":"2013","journal-title":"Apoptosis"},{"key":"10.1016\/j.bbcan.2014.05.004_bb0370","doi-asserted-by":"crossref","first-page":"427","DOI":"10.7314\/APJCP.2014.15.1.427","article-title":"IDH1 overexpression induced chemotherapy resistance and IDH1 mutation enhanced chemotherapy sensitivity in Glioma cells in vitro and in vivo","volume":"15","author":"Wang","year":"2014","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0375","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1200\/JCO.2013.49.3726","article-title":"Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH","volume":"32","author":"Cairncross","year":"2014","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0380","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1007\/s12272-010-0713-4","article-title":"Silencing of cytosolic NADP+-dependent isocitrate dehydrogenase gene enhances ethanol-induced toxicity in HepG2 cells","volume":"33","author":"Yang","year":"2010","journal-title":"Arch. Pharm. Res."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0385","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.biochi.2009.05.008","article-title":"Regulation of ethanol-induced toxicity by mitochondrial NADP(+)-dependent isocitrate dehydrogenase","volume":"91","author":"Yang","year":"2009","journal-title":"Biochimie"},{"key":"10.1016\/j.bbcan.2014.05.004_bb0390","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1080\/10715760802653661","article-title":"Silencing of cytosolic NADP(+)-dependent isocitrate dehydrogenase by small interfering RNA enhances the sensitivity of HeLa cells toward staurosporine","volume":"43","author":"Lee","year":"2009","journal-title":"Free Radic. Res."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0395","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.bbrc.2013.02.093","article-title":"Silencing of mitochondrial NADP(+)-dependent isocitrate dehydrogenase gene enhances glioma radiosensitivity","volume":"433","author":"Kim","year":"2013","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0400","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/j.freeradbiomed.2007.07.009","article-title":"Small interfering RNA-mediated silencing of mitochondrial NADP+-dependent isocitrate dehydrogenase enhances the sensitivity of HeLa cells toward tumor necrosis factor-alpha and anticancer drugs","volume":"43","author":"Kil","year":"2007","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0405","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jdermsci.2011.12.007","article-title":"Expression of cytosolic NADP(+)-dependent isocitrate dehydrogenase in melanocytes and its role as an antioxidant","volume":"65","author":"Kim","year":"2012","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0410","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.freeradbiomed.2006.09.016","article-title":"Oxalomalate regulates ionizing radiation-induced apoptosis in mice","volume":"42","author":"Lee","year":"2007","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0415","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.biocel.2012.01.017","article-title":"Glioma derived isocitrate dehydrogenase-2 mutations induced up-regulation of HIF-1alpha and beta-catenin signaling: possible impact on glioma cell metastasis and chemo-resistance","volume":"44","author":"Fu","year":"2012","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0420","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/nature07733","article-title":"Association of reactive oxygen species levels and radioresistance in cancer stem cells","volume":"458","author":"Diehn","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2014.05.004_bb0425","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.mehy.2013.02.022","article-title":"NADP+-dependent IDH1 R132 mutation and its relevance for glioma patient survival","volume":"80","author":"Baldewpersad Tewarie","year":"2013","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.bbcan.2014.05.004_bb0430","series-title":"Study of AG-221 in Subjects With Advanced Hematologic Malignancies With an IDH2 Mutation","author":"Phase","year":"2014"},{"key":"10.1016\/j.bbcan.2014.05.004_bb0435","doi-asserted-by":"crossref","first-page":"8981","DOI":"10.1158\/0008-5472.CAN-10-1666","article-title":"Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1","volume":"70","author":"Seltzer","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2014.05.004_bb1110","article-title":"Inhibition of glutaminase selectively suppresses the growth of primary AML Cells with IDH mutations","author":"Emadi","year":"2013","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.bbcan.2014.05.004_bb1115","doi-asserted-by":"crossref","DOI":"10.1158\/2159-8290.CD-13-0572","article-title":"A high-throughput fluorimetric assay for 2-hydroxyglutarate identifies Zaprinast as a glutaminase inhibitor","author":"Elhammali","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0450","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1097\/00000658-199312000-00004","article-title":"Glutamine and cancer","volume":"218","author":"Souba","year":"1993","journal-title":"Ann. Surg."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0455","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/onc.2009.358","article-title":"Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer","volume":"29","author":"DeBerardinis","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.bbcan.2014.05.004_bb0460","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature13110","article-title":"Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides","volume":"508","author":"Birsoy","year":"2014","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bbcan.2014.05.004_bb1120","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/leu.2013.269","article-title":"Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms","volume":"28","author":"Traina","year":"2014","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.bbcan.2014.05.004_bb1125","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.3109\/10428194.2013.840777","article-title":"Case series of patients with acute myeloid leukemia receiving hypomethylation therapy and retrospectively found to have IDH1 or IDH2 mutations","volume":"55","author":"Benton","year":"2014","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.bbcan.2014.05.004_bb0475","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.cell.2012.07.023","article-title":"Cancer vulnerabilities unveiled by genomic loss","volume":"150","author":"Nijhawan","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.bbcan.2014.05.004_bb0480","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature11331","article-title":"Passenger deletions generate therapeutic vulnerabilities in cancer","volume":"488","author":"Muller","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2014.05.004_bb0485","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1016\/j.bcp.2011.07.093","article-title":"Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications","volume":"82","author":"Singh","year":"2011","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bbcan.2014.05.004_bb0490","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/0005-2744(76)90180-7","article-title":"Mechanism of the inhibitory effect of glyoxylate plus oxaloacetate and oxalomalate on the NADP-specific isocitrate dehydrogenase","volume":"452","author":"Ingebretsen","year":"1976","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bbcan.2014.05.004_bb0495","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s11060-008-9706-2","article-title":"Hydroxyglutaric aciduria and malignant brain tumor: a case report and literature review","volume":"91","author":"Aghili","year":"2009","journal-title":"J. Neurooncol."},{"key":"10.1016\/j.bbcan.2014.05.004_bb1130","first-page":"2863","article-title":"Nanoparticles for hyperthermic therapy: synthesis strategies and applications in glioblastoma","volume":"9","author":"Verma","year":"2014","journal-title":"J. Int. Neuromed."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X14000493?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X14000493?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,10]],"date-time":"2019-08-10T22:57:55Z","timestamp":1565477875000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304419X14000493"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":202,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["S0304419X14000493"],"URL":"https:\/\/doi.org\/10.1016\/j.bbcan.2014.05.004","relation":{},"ISSN":["0304-419X"],"issn-type":[{"value":"0304-419X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongation","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbcan.2014.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}